Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Schizophrenia, food and drug administration
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This drug takes the first new approach to schizophrenia treatment in decades,” the Food and Drug Administration said.
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
BioWorld
14h
Karxt for schizophrenia awaits US FDA decision; inventor opines
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
2d
on MSN
The 'game-changing' treatment for schizophrenia
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
Medscape
6d
Will 'Game-Changer' Antipsychotic Live Up to the Hype?
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Promotes watch collection
Killer gets life sentence
World's oldest cheese found
Fake Biden robocalls fine
Producing doc on Diddy
Ending password-sharing
50/50 ball ownership suit
Boxes to distribute Narcan
Urgent safety alert for 737s
US sanctions crypto network
Targeted Black residents?
Stadiums to serve as shelters
OK's new schizophrenia drug
Chinese submarine sank
More executives leave
On Secret Service failures
WI duplicate ballot flap
NC board removes 747K
NIH finds misconduct
Arrives in Luxembourg
Kotb leaving 'Today'
Capital goods orders up
Rose announces retirement
US economy grew
Military recruiting rebounds
To withdraw sickle cell drug
Settles defamation lawsuit
RU hits Ukraine's power grid
US suicides steady, high
Feedback